AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer

AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer

March 21, 2013

 

AstraZeneca today announced an exclusive agreement with Moderna Therapeutics to discover, develop and commercialise pioneering messenger RNA therapeutics™ for the treatment of serious cardiovascular, metabolic and renal diseases as well as cancer. Messenger RNA therapeutics™ are an entirely new treatment approach that enables the body to produce therapeutic protein in vivo, opening up new treatment options for a wide range of diseases that cannot be addressed today using existing technologies.

Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation

Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation

April 10, 2012

Initiative combines Merck’s drug development expertise with Flagship’s experience in building early stage companies

BIND Therapeutics Co-Founder Publishes Nanotechnology Article in the Journal of the American Medical Association

BIND Therapeutics Co-Founder Publishes Nanotechnology Article in the Journal of the American Medical Association

January 22, 2015

− Prof. Robert S. Langer provides insight on potential for application of nanomedicine in broad therapeutic areas −

Eleven Biotherapeutics Appoints Barry Gertz, MD, PhD, and Jay S. Duker, MD, to Board of Directors

Eleven Biotherapeutics Appoints Barry Gertz, MD, PhD, and Jay S. Duker, MD, to Board of Directors

January 22, 2015

 - Leaders in Industry and Academia Join Board as Eleven’s Ocular Pipeline Advances –

Seres Health Announces Addition of Mark Wilcox, M.D. to Scientific Advisory Board

Seres Health Announces Addition of Mark Wilcox, M.D. to Scientific Advisory Board

January 21, 2015

CAMBRIDGE, Mass., Jan. 21, 2015 /PRNewswire/ -- Seres Health, Inc., a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat diseases by restoring the function of a dysbiotic microbiome, announced today the addition of Mark Wilcox, M.D., of the University of Leeds, to its Scientific Advisory Board (SAB).

Avedro Appoints Brian Roberts as Chief Financial Officer

Avedro Appoints Brian Roberts as Chief Financial Officer

January 20, 2015

 WALTHAM, Mass.--()--Avedro Inc., a Boston-based ophthalmic pharmaceutical and medical device company announced today that Brian K. Roberts is joining the company as its new Chief Financial Officer. In this position, Mr.

Report Published in The Journal of the American Medical Association Highlights Impact of T2 Biosystems' T2MR Technology in Diagnosing Infections

Report Published in The Journal of the American Medical Association Highlights Impact of T2 Biosystems' T2MR Technology in Diagnosing Infections

January 13, 2015

Paper Co-Authored by T2 Biosystems' Co-Founders Dr. Robert Langer and Dr. Ralph Weissleder Underscores Potential for T2MR Over Existing Diagnostic Methodologies

Seres Health Appoints Shelley Trucksis, Ph.D., M.D. as Executive Vice President and Chief Medical Officer

Seres Health Appoints Shelley Trucksis, Ph.D., M.D. as Executive Vice President and Chief Medical Officer

January 15, 2015

CAMBRIDGE, Mass., Jan.15, 2015 /PRNewswire/ -- Seres Health, Inc., a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat diseases by restoring the function of a dysbiotic microbiome, today announced the appointment of Michele (Shelley) Trucksis, Ph.D., M.D., as Executive Vice President and Chief Medical Officer. In this role, Dr. Trucksis will be responsible for overseeing the clinical development and operations of Seres' Ecobiotic® product pipeline.

Oasys Water’s Global Momentum Continues with Asia-Pacific Expansion and Deployment of its Forward Osmosis Systems

Oasys Water’s Global Momentum Continues with Asia-Pacific Expansion and Deployment of its Forward Osmosis Systems

January 13, 2015

 Water Treatment and Desalination Innovator Completes First Commercial Year Expanding its International Reach

Moderna Announces License and Collaboration Agreement with Merck to Develop Messenger RNA-based Antiviral Vaccines and Passive Immunity Therapies

Moderna Announces License and Collaboration Agreement with Merck to Develop Messenger RNA-based Antiviral Vaccines and Passive Immunity Therapies

January 13, 2015

 CAMBRIDGE, Mass., January 13, 2015 – Moderna Therapeutics today announced a license and collaboration agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary, for the discovery and development of vaccines and passive immunity treatments against viral diseases using modified messenger RNA (mRNA). Moderna is a pioneer in the development of mRNA Therapeutics™ across a range of therapeutic applications.